TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8796408
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of muscle relaxant
Study: 1636580
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (1200 mg/day for 14 days)
Study: 1636580
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (2400 mg/day for 7 days)
Study: 4032694
Drug: Ordinary dose
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary dose fentanyl (15 mcg/kg)
Study: 4032694
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose fentanyl (37 mcg/kg)
Study: 30408115
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB LA 600 mg IM every 8 weeks
Study: 30408115
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB LA 800 mg IM every 12 weeks
Study: 30408115
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB LA (both doses)
Study: 26537369
Drug: Minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline hydrochloride ointment (MHO)
Study: 26537369
Drug: Erythromycin eye
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin eye ointment (EEO)
Study: 22333852
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin analogues (PGAs) administered over 24 weeks
Study: 20833738
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at a target dose of 2 g/day
Study: 20833738
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) at a target dose of 2 mg/kg/day
Study: 16338269
Drug: Multiple antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple antihypertensive agents
Study: 11889016
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide pulse therapy
Study: 10567782
Drug: gemifloxacin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemifloxacin administration
Study: 220733
Drug: Adriamycin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (40 mg/m2) given every 4 weeks
Study: 220733
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment group (15 patients)
Study: 31675184
Drug: Robotic-assisted passive
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted passive movement treatment
Study: 22042958
Drug: paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel plus sequential trastuzumab weekly for 52 weeks (arm B)
Study: 22042958
Drug: paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel plus concurrent trastuzumab for 12 weeks followed by trastuzumab for 40 weeks (arm C)
Study: 22042958
Drug: doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by paclitaxel weekly for 12 weeks (arm A)
Study: 17005077
Drug: Nourishing yin
Normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nourishing yin and Unblocking meridians Recipe (NUR) combined with opioid analgesics
Study: 18590407
Drug: Opioid analgesics
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesics alone
Study: 11549098
Drug: Ezetimibe (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (daily doses ranging from 0.25 to 10 mg for 12 weeks)
Study: 31628524
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus first-line chemotherapy (paclitaxel plus carboplatin)
Study: 31628524
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (paclitaxel plus carboplatin)
Study: 22011016
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS (high-frequency over left dorsolateral prefrontal cortex for 25 minutes) plus individualized speech therapy
Study: 22011016
Drug: Placebo rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rTMS plus individualized speech therapy
Study: 18611959
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of oral amoxycillin
Study: 16481188
Drug: Intrapleural intercostal
Normalized name: INTRAPLEURAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural intercostal nerve block (IINB) with 20 ml (7.5 mg/ml) ropivacain injection at the dose of 4 ml for each space from the 4th to the 8th space.
Study: 10690696
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation for malnourished residents (score <17)
Study: 10690696
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation for residents at risk of malnutrition (score 17-23.5)
Study: 10690696
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral supplementation for residents with score 24
Study: 9339691
Drug: tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone 200 mg tid
Study: 9339691
Drug: tolcapone 100
Normalized name: tolcapone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone 100 mg tid
Study: 8274414
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy for 1 month (n = 12)
Study: 8274414
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy for 24 hours (n = 7)
Study: 3011048
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments (oral and intravenous trimazosin)
Study: 27874935
Drug: BLIS K12
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLIS K12 (Bactoblis) daily for 6 months
Study: 26145468
Drug: Salt treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt treatment for 17 days along with dental sanitation and treatment of gingivitis
Study: 19020153
Drug: Intranasal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal morphine 7.5 mg
Study: 19020153
Drug: Intranasal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal morphine 15 mg
Study: 19020153
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 7.5 mg
Study: 19020153
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine 60 mg
Study: 16877482
Drug: Ciclosporin A
Normalized name: Ciclosporin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin A to tacrolimus conversion (group A, target tacrolimus trough level 6-8 ng/ml)
Study: 16877482
Drug: Ciclosporin A
Normalized name: Ciclosporin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin A minimization (group B, target CsA trough level 80-100 ng/ml)
Study: 10385545
Drug: Cisplatin-based treatment
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based treatment after cytoreductive surgery
Study: 8630559
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nebulized natural-derived bovine surfactant (Alveofact)
Study: 28978542
Drug: Whole eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole eggs (18 g protein, 17 g fat)
Study: 28978542
Drug: Egg whites
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg whites (18 g protein, 0 g fat)
Study: 1362592
Drug: Antiparkinsonian drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparkinsonian drugs withdrawal
Study: 3890428
Drug: Hyperbaric oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygenation (HBO) in multiple modality therapy
Study: 3890428
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without HBO
Study: 27770801
Drug: Balance chiropractic
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance chiropractic therapy (BCT)
Study: 22424834
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (verteporfin 6 mg/m² PDT and ranibizumab 0.5 mg)
Study: 22424834
Drug: Ranibizumab monotherapy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monotherapy (sham infusion [5% dextrose] PDT and ranibizumab 0.5 mg)
Study: 19996947
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (300 mg loading dose followed by 15 mg/kg/24h for 2 days)
Study: 18292850
Drug: FPs' perception
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPs' perception of treatment compliance
Study: 15996628
Drug: Esomeprazole 20mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20mg, levofloxacin 500 mg and azithromycin 500 mg once-daily (ELAz)
Study: 15996628
Drug: Esomeprazole 20mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20mg, clarithromycin 500 mg and amoxycillin 1g twice-daily (ECA)
Study: 30466191
Drug: Mealtime fast-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mealtime fast-acting insulin aspart
Study: 30394552
Drug: Transfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion with one unit of RBCs at a hemoglobin level of 9.0 g/dL
Study: 30394552
Drug: Transfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion with one unit of RBCs at a hemoglobin level of 7.0 g/dL
Study: 26577998
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Levofloxacin + Terazosin)
Study: 26577998
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Levofloxacin, Terazosin, Combination)
Study: 25247319
Drug: Cytological examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytological examination using a capsule sponge device
Study: 22539051
Drug: Scalp cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp cooling with 90-min post-infusion cooling time (PICT)
Study: 16786786
Drug: Methods for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methods for prevention and treatment of postoperative nausea and vomiting (PONV)
Study: 12730560
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (rtPA; Actilyse) administered up to 6 hours after stroke
Study: 10632905
Drug: Presurgical axillary
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical axillary block with 2 mg.kg-1 of 0.25% bupivacaine
Study: 10632905
Drug: Postsurgical axillary
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postsurgical axillary block with 2 mg.kg-1 of 0.25% bupivacaine
Study: 8701508
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract GB‐8 at a dose of 120 mg o.d.
Study: 1953853
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin after four hours of observation
Study: 1953853
Drug: Intravaginal 3
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 3 mg PGE2 gel followed by intravenous oxytocin four hours later
Study: 6602328
Drug: Aspirin 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 4.0 g/day
Study: 6602328
Drug: Diflunisal 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 1,000 mg/day
Study: 25079399
Drug: Proximal hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal hygiene treatment (study 1)
Study: 23866471
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg) given orally at 10:00 pm the night before operation and at 7:00 am on the day of surgery
Study: 18599252
Drug: Recursive partitioning
Normalized name: Immunoglobulin g1, anti-(human repulsive guidance molecule rgma) (human-mus musculus clone rh116a3 .gamma.1-chain), disulfide with human-mus musculus clone rh116a3 .kappa.-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recursive partitioning (RP) methodology applied to drug treatment retention analysis
Study: 17697500
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists (GnRHa) plus gonadotrophin therapy with corticosteroids (dexamethasone)
Study: 17697500
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists (GnRHa) plus gonadotrophin therapy with placebo
Study: 16138974
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib (0.3 mg)
Study: 16138974
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib (1.0 mg)
Study: 16138974
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib (3.0 mg)
Study: 16138974
Drug: Subconjunctival sham
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival sham injection (Control)
Study: 9449910
Drug: 0.05% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tazarotene gel administered once or twice daily
Study: 9449910
Drug: 0.1% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tazarotene gel administered once or twice daily
Study: 31038476
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification treatment (diet, rehabilitation, education, behavioral therapy) for 12 weeks
Study: 27748623
Drug: Liposomal amikacin
Normalized name: amikacin liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal amikacin for inhalation (LAI) 590 mg once daily for 84 days
Study: 23279373
Drug: Sitagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50 mg/day, increased to 100 mg/day if HbA1c ≥6.5% at 16 weeks)
Study: 23279373
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg/day, increased to 30 mg/day if HbA1c ≥6.5% at 16 weeks)
Study: 19786145
Drug: Polypeptide vaccine
Normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypeptide vaccine (EP-1043)
Study: 15297403
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC = 5.5 mg/ml x min day 1) and gemcitabine (1000 mg/m(2) days 1 and 8 every 21 days x 3) followed by paclitaxel (225 mg/m(2) every 21 days x 3)
Study: 15297403
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m(2) day 1), vinorelbine (25 mg/m(2) days 1 and 8 every 21 days x 3) followed by docetaxel (75-100 mg/m(2) every 21 days x 3)
Study: 11707557
Drug: Very-low-calorie diets
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-calorie diets (VLCDs) with active follow-up treatment including behavior therapy, nutritional education, and exercise
Study: 7867399
Drug: Selenium supplement
Normalized name: Selenium supplement
DrugBank: Selenious acid (DB11127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplement (100 micrograms/d for 6-8 weeks)
Study: 7867399
Drug: Selenium supplement
Normalized name: Selenium supplement
DrugBank: Selenious acid (DB11127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplement
Study: 1030548
Drug: Initial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial and crossover chemotherapy
Study: 23737390
Drug: Other drug-eluting
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug-eluting stents (DES)
Study: 19372620
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg or 40 mg
Study: 1824048
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitors (MAOI)
Study: 25888525
Drug: Albendazole (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (three monthly treatments for one year, three consecutive days of supervised drug intake)
Study: 25888525
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (three monthly treatments for one year, three consecutive days of supervised drug intake)
Study: 25117425
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (180 μg/week) + Ribavirin (1000/1200 mg/day)
Study: 25117425
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2b (1.5 μg/kg/week) + Ribavirin (1000/1200 mg/day)
Study: 22378331
Drug: Sweet preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet preload (0.35 L fruit juice)
Study: 22378331
Drug: Savory preload
Normalized name: winter savory oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savory preload (0.35 L tomato juice)
Study: 25885239
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (1 mg/kg) (n=20)
Study: 25885239
Drug: Rectal tramadol
Normalized name: tramadol hydrochloride Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal tramadol (1.5‐2 mg/kg, maximum 100 mg) (n=20)
Study: 17671253
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg weekly intramuscular injections
Study: 16225528
Drug: Dicyclomine 20
Normalized name: dicyclomine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicyclomine 20 mg four times daily
Study: 12385694
Drug: Ertapenem 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1.5 g
Study: 12385694
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g and 1.5 g
Study: 10233270
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine for 1 week
Study: 10233270
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine for 2 weeks
Study: 10233270
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine for an additional 4 weeks (for non-responders)
Study: 10233270
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine for an additional 4 weeks (for Microsporum infections)
Study: 7479198
Drug: Ascorbate 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbate 4.5 g/day
Study: 4901340
Drug: Bordetella pertussis
Normalized name: Bordetella pertussis
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bordetella pertussis vaccine
Study: 15384292
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block plus labial infiltration (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 15384292
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block alone (3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 9648960
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 microg (2x100 microg) via metered dose inhaler with a spacer
Study: 8024992
Drug: Etodolac 300
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 300 mg twice daily for 4 weeks
Study: 8024992
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for 4 weeks
Study: 30531234
Drug: Lofexidine 2.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine 2.16 mg/d
Study: 30531234
Drug: Lofexidine 2.88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine 2.88 mg/d
Study: 20104189
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg alone or in association with 12.5 or 25 mg hydrochlorothiazide (HCTZ)
Study: 20104189
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg in association with 25 mg HCTZ
Study: 20104189
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg in association with 25 mg HCTZ
Study: 20104189
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg in association with 25 mg HCTZ
Study: 14961168
Drug: Inogatran (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (low molecular weight direct thrombin inhibitor)
Study: 7907731
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of 1 g of gliadin
Study: 21679485
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g oligofructose
Study: 10393452
Drug: Commercial BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial BPO formulation
Study: 10393452
Drug: Pharmacopoeial BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacopoeial BPO formulation
Study: 6839799
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (3 g)